Prosser v. Pharmalogic Holdings Corp.

Superior Court of Delaware·Decided July 7, 2026·No. N25C-08-284 MAA CCLD·Published

Opinion

IN THE SUPERIOR COURT OF THE STATE OF DELAWARE

RODNEY PROSSER, individually ) and as Sellers’ Representative, ) FRANK RUDDY, and KOK ) C.A. No. N25C-08-284 MAA CCLD WAYNE WONG, ) ) Plaintiffs, ) ) v. ) ) PHARMALOGIC HOLDINGS ) CORP., ) ) Defendant. )

Submitted: April 22, 2026 Decided: July 7, 2026

Defendant’s Motion to Dismiss the Amended Complaint: GRANTED in part; DENIED in part.

MEMORANDUM OPINION

John H. Newcomer, Jr., Esquire, Kirsten A. Zeberkiewicz, Esquire, Barnaby Grzaslewicz, Esquire (Argued), Alena Smith, Esquire, MORRIS JAMES LLP, Wilmington, DE. Attorneys for Plaintiffs.

Ryan D. Stottmann, Esquire, Cassandra L. Baddorf, Esquire, MORRIS, NICHOLS, ARSHT & TUNNELL LLP, Wilmington, DE; Joseph P. Rockers, Esquire (Argued), Brendan Blake, Esquire, GOODWIN PROCTER LLP, Boston, MA. Attorneys for Defendant PharmaLogic Holdings Corp.

Adams, J. INTRODUCTION

This action concerns a dispute between the buyer and sellers of a business

over a post-closing earnout scheme. The sellers contend the buyer changed the

operations of the business to reduce EBITDA and avoid an earnout payment, in

violation of the parties’ contract. The buyer moved to dismiss, contending the

sellers’ breach of contract claim is subject to an alternative dispute resolution

provision which requires resolution of the claim before an independent auditor, is

time barred, and fails to state a claim for which relief can be granted. For the reasons

explained herein, the Court disagrees with the buyer and denies the motion as to the

breach of contract claim.

Separately, the sellers bring a declaratory judgment claim seeking a

declaration that the buyer materially breached the parties’ contract and therefore the

sellers are excused from bringing their breach of contract claims before the

independent auditor. The buyer contends the sellers waived this argument by

continuing to perform under the contract after the purported material breach. The

Court agrees with the buyer but finds the relevant breach claim was nonetheless not

subject to the independent auditor’s review.

Finally, the sellers contend that the business sold to the buyer received tax

refunds for pre-closing tax payments and that the sellers are entitled to those refunds

because the business was treated a pass-through entity for taxation purposes.

1 Because the parties’ contract does not explicitly address this issue, sellers contend

their claims for the tax refund are viable pursuant to the implied covenant of good

faith and fair dealing’s gap-filling capabilities or the doctrine of unjust enrichment.

The buyer contends the existence of a contract which comprehensively addresses tax

issues precludes these claims. For the reasons explained herein, the Court agrees

with the buyer. This Memorandum Opinion resolves the buyer’s motion to dismiss.

FACTS

The factual background outlined herein is drawn from the Amended

Complaint, 1 accepting all well-pled allegations as true only for purposes of this

Motion, as is required for a Rule 12(b)(6) motion to dismiss.2 The Court will not

necessarily use terms like “alleged” throughout. The Court intends to convey no

agreement with the truth of the matters asserted in the Complaint. The veracity of

the Complaint’s allegations can be resolved after discovery.

I. The Parties

Plaintiffs Rodney Prosser, Frank Ruddy, and Kok Wayne Wong (“Plaintiffs”)

are individuals residing in New Jersey.3 Defendant PharmaLogic Holdings Corp. is

a Delaware Corporation (Defendant).4 Plaintiffs founded and developed a nuclear

1 D.I. 13. Citations to the Amended Complaint are in the form of “AC ¶ X.” Citations to exhibits to the Amended Complaint are in the form of “AC Ex. X.” 2 Cent. Mortg. Co. v. Morgan Stanley Mortg. Cap. Hldgs. LLC, 27 A.3d 531, 536 (Del. 2011). 3 AC ¶¶ 8-10. 4 Id. ¶ 11. 2 pharmacy business (the “Business”), which they sold to Defendant pursuant to the

Parties’ Securities Purchase Agreement (“SPA”).5 Under the SPA, Plaintiffs are the

“Sellers,” and Defendant is the “Buyer.”6

II. Plaintiffs sell the Business.

Plaintiffs operated the Business out of two pharmacy locations in New Jersey

and one in New York. 7 In 2015, Plaintiffs began contemplating retirement and

sought to sell the Business. 8 Plaintiffs and Defendant commenced negotiations

regarding a potential sale, ultimately culminating in the execution of the SPA on

March 20, 2020.9 The sale of the business closed on January 6, 2021.10

Under the SPA, Plaintiffs sold the Business for $30,000,000 plus an earnout

payment.11 Pursuant to the Earnout Provision, the SPA provides that, if the business

hit certain earnings before interest, taxes, depreciation, and amortization

(“EBITDA”) levels by a certain date (an earnout target), Plaintiffs would be entitled

to an additional payment. 12 Specifically for purposes of this action, the earnout

5 Id. ¶ 2. 6 Id. ¶¶ 8-11. 7 Id. ¶ 17. 8 Id. ¶ 18. 9 AC ¶ 22. 10 Id. 11 Id. ¶ 23; AC Ex. 1 (“SPA”) at 1. 12 SPA § 2.6. Section 2.6 provides, in part: if, during the Earnout Period, the Company achieves EBITDA greater than or equal to $7,000,000, but less than or equal to $7,499,999, Buyer shall pay to the Sellers’ Representative, for further distribution by the Sellers’ Representative to the Sellers in accordance with the allocations set forth on Schedule 2.3(c), $6,600,000, as an additional purchase price payment, pursuant to the procedures set forth in this 3 provision provided that, if the Business’s EBITDA, at the assessment date, lay

between $7 million and $7.5 million, Plaintiffs would be entitled to a earnout

payment of $6.6 million. 13 Pursuant to an amendment to the SPA, the relevant

earnout period after which the EBITDA would be assessed was defined as the twelve

months following July 1, 2021.14 During this earnout period, Defendant’s authority

to manage the Business was restricted, as they promised “to act in good faith and

operate the Business in a manner that is not designed or intended to impede or

interfere with EBTIDA and not take, or cause to be taken, any action intended to

decrease EBITDA.”15

Pursuant to the SPA, after the earnout period closed, Defendant was to present

an EBITDA calculation, “prepared in good faith,” to Plaintiffs “together with

reasonably detailed supporting documentation” (the “Earnout Statement”). 16

Plaintiffs would have the opportunity to dispute the Earnout Statement via a notice

of non-acceptance, potentially triggering resolution via an independent auditor. 17

Section 2.6;… if, during the Earnout Period, the Company achieves EBITDA greater than or equal to $7,500,000, but less than or equal to $7,999,999, Buyer shall pay to the Sellers’ Representative, for further distribution by the Sellers’ Representative to the Sellers in accordance with the allocations set forth on Schedule 2.3(c), $9,900,000, as an additional purchase price payment, pursuant to the procedures set forth in this Section 2.6;…et cetera. 13 SPA § 2.6(a)(i). 14 AC Ex. 2. 15 SPA § 2.6(e) (citation modified). 16 Id. § 2.6(b). 17 Id. § 2.6(c). 4 During the earnout period, Defendant was to provide Plaintiffs with (at least)

quarterly reports, including “a written statement showing an estimated calculation

of EBITDA based on the period beginning on the day after the Closing Date through

Free access — add to your briefcase to read the full text and ask questions with AI

Prosser v. Pharmalogic Holdings Corp., (Del. Ct. App. 2026).

Prosser v. Pharmalogic Holdings Corp. (Prosser v. Pharmalogic Holdings Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In Re Tyson Foods, Inc. Consolidated Shareholder Litigation
919 A.2d 563 (Court of Chancery of Delaware, 2007)
Nemec v. Shrader
991 A.2d 1120 (Supreme Court of Delaware, 2010)
In Re Tri-Star Pictures, Inc., Litigation
634 A.2d 319 (Supreme Court of Delaware, 1993)
DCV Holdings, Inc. v. ConAgra, Inc.
889 A.2d 954 (Supreme Court of Delaware, 2005)